Loading
A phase 2 trial of NKT2152 run by NiKang Therapeutics, Inc., terminated.
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) is a phase 2 interventional study registered as NCT05935748 by NiKang Therapeutics, Inc., with 18 participants enrolled, started 2023-07-28, primary completion reached 2025-06-30. Conditions recorded: ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Carcinoma, Neoplasms, Carcinoma, Renal Cell, Neoplasms, Glandular and Epithelial, Neoplasm by Histology, Adenocarcinoma, Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Kidney Diseases, Urologic Diseases. Interventions recorded: NKT2152, palbociclib, sasanlimab. Reason given for stopping: This study was terminated as a result of Sponsor portfolio reprioritization.
Shares NKT2152, NiKang Therapeutics, Clear cell renal cell carcinoma and the tag pipeline.
Shares NiKang Therapeutics and the tag pipeline.
Shares NiKang Therapeutics and the tag pipeline.
Shares NiKang Therapeutics and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares NiKang Therapeutics and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/